South Korean health technology company Neurofet has received certification from Singapore’s Health Sciences Authority for its AI-enabled psychiatric diagnostic assistant software. Its flagship software, Neurofet Aqua, uses AI to analyze brain MRIs to detect brain atrophy and white matter degeneration, as seen in neurodegenerative diseases such as Alzheimer’s disease and vascular disease. The company claims the product can segment and analyze brain images in five minutes with a 0% analysis failure rate. Why It Matters Neurofet is looking to tap into Singapore’s medical industry, which is forecast to grow to about $49 billion by 2029. The company first entered the market with Neurofet-scale PET, which combines PET of the brain to scan for biomarkers of Alzheimer’s disease. and MRI images. It also received HSA approval for this late last year. The big trend is that the company is working double-time to further penetrate the large Southeast Asian market by collaborating with the Dementia Research Center under the Lee Kong Chian School of Medicine at Nanyang Technological University in Singapore to conduct multidisciplinary brain disease research that validates AI software offerings. In December, the company partnered with medical device distributor Clairvo Technologies to expand Neurofet Aqua’s reach in the Japanese market.